• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Ergomed - Articles and news items


Aeterna Zentaris’ Zoptrex granted licensing agreement for Australia and New Zealand

Industry news / 14 October 2016 / Niamh Louise Marriott, Digital Content Producer

Zoptrex, a novel synthetic peptide carrier linked to doxorubicin, is currently in a fully-enrolled Phase 3 clinical trial in endometrial cancer…

Ergomed and Ferrer complete recruitment for Phase IIa insomnia clinical trial

Industry news / 13 September 2016 / Niamh Louise Marriott, Digital Content Producer

The effects of lorediplon (5 and 10 mg) are being compared to both placebo and zolpidem. The aim of the study is to evaluate the appropriate effective dose of lorediplon, to further characterise its efficacy on sleep maintenance/sleep quality and to evaluate any next day hangover effects in adult patients with insomnia disorder…

Asian licensing deals for Ergomed and Aeterna Zentaris’ endometrial cancer drug

Industry news / 6 September 2016 / Niamh Louise Marriott, Digital Content Producer

Aeterna Zentaris signed an exclusive license agreement with affiliates of Orient EuroPharma for its lead anti-cancer compound, zoptrex, for the initial…

Ergomed proposes acquisition of Haemostatix

Industry news / 5 May 2016 / Victoria White, Digital Content Producer

Ergomed is acquiring 100% of the issued share capital of Haemostatix for an initial consideration of £8.0 million…


Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +